ReviewPlants (Basel, Switzerland)2025
Complexity Meets Risk-The Next Generation of Genome-Edited Plants Challenges Established Concepts for Environmental Risk Assessment in the EU.
Review in Plants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Paradigm shift in apomixis research: Targeting mutants with elements of apomixis in sexual crops.Planta · 2026Review
- Gene Flow and Hybridization Potential Between GM/NGT Crops and Conventional Varieties or Wild Relatives: A Scoping Literature Review with Emphasis on Oilseed Rape (Biotech (Basel (Switzerland)) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
For 20 years, the environmental risk assessment (ERA) of genetically modified plants (GMPs) has used a comparative assessment approach, comparing the GMP to presumably safe and familiar non-modified plant varieties. With new genomic techniques, it is now possible to design complex GMP applications with systemic metabolic changes, resulting in novel plant phenotypes. These plant phenotypes can exhibit profoundly altered morphological, physiological, or compositional characteristics, intentionally lacking equivalence with parental plants and non-modified comparators. Through the analysis of case studies involving GMPs with modifications of complex metabolic pathways, we evaluate the current practice of the comparative safety assessment approach applied in ERA in the European Union and its ability to inform ERA, particularly regarding environmental risks. Our findings show that the existing approach has notable weaknesses when applied to complex GMP applications. We suggest complementing ERA with a hypothesis-driven assessment approach that considers various protection goals and relies on whole-plant experimental assessments to draw risk conclusions. As plant modifications become increasingly complex, such as the development of synthetic biology plants, conducting ecologically realistic assessments will be crucial for future ERA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.